» Articles » PMID: 39127981

Acute Presentation of Autoimmune Hepatitis -from Acute Hepatitis to ALF and ACLF

Overview
Journal Hepatol Int
Publisher Springer
Specialty Gastroenterology
Date 2024 Aug 11
PMID 39127981
Authors
Affiliations
Soon will be listed here.
Abstract

Acute presentation of autoimmune hepatitis (AIH) occurs in 22-43% of all AIH cases, and is not a rare condition. Rather than constituting a single disease entity, it represents a clinical spectrum characterized by considerable variability in severity and the presence of preexisting chronic AIH. This spectrum ranges from acute AIH and acute severe AIH to AIH presenting as acute liver failure (ALF) or as acute-on-chronic liver failure (ACLF), contingent upon factors such as coagulopathy, hepatic encephalopathy, and underlying liver disease. Diagnosing acute presentation of AIH can be particularly challenging due to the frequent absence of classical serologic signatures such as autoantibodies and elevated IgG levels. Histopathological examination remains essential for diagnosis, typically necessitating percutaneous or transjugular liver biopsy. Corticosteroids (CS) are recommended for the management of acute AIH and acute severe AIH with coagulopathy. However, the therapeutic response to CS should be meticulously monitored. If a poor response is anticipated, liver transplantation (LT) should be promptly considered. For AIH presenting as ALF with encephalopathy or ACLF with advanced underlying liver disease, LT is generally advised. Nonetheless, there is potential for a trial of CS therapy in cases of ALF with low MELD scores or ACLF without encephalopathy. This review provides an overview of the latest findings concerning the definition, diagnosis, and management of acute presentation of AIH.

Citing Articles

Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.

Choudhury A, Kulkarni A, Arora V, Soin A, Dokmeci A, Chowdhury A Hepatol Int. 2025; 19(1):1-69.

PMID: 39961976 PMC: 11846769. DOI: 10.1007/s12072-024-10773-4.

References
1.
Ohira H, Takahashi A, Zeniya M, Abe M, Arinaga-Hino T, Joshita S . Clinical practice guidelines for autoimmune hepatitis. Hepatol Res. 2022; 52(7):571-585. DOI: 10.1111/hepr.13776. View

2.
Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K . The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021; 15(2):223-257. PMC: 8144150. DOI: 10.1007/s12072-021-10170-1. View

3.
Muratori P, Carbone M, Stangos G, Perini L, Lalanne C, Ronca V . Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study. Dig Liver Dis. 2018; 50(7):698-702. DOI: 10.1016/j.dld.2018.02.015. View

4.
Shen Y, Lu C, Men R, Liu J, Ye T, Yang L . Clinical and Pathological Characteristics of Autoimmune Hepatitis with Acute Presentation. Can J Gastroenterol Hepatol. 2018; 2018:3513206. PMC: 5878912. DOI: 10.1155/2018/3513206. View

5.
Sonthalia N, Jain S, Thanage R, Junare P, Chandnani S, Pawar V . Clinical, serological, histopathological and treatment profile of autoimmune hepatitis in the elderly. Clin Exp Hepatol. 2020; 6(1):13-19. PMC: 7062115. DOI: 10.5114/ceh.2020.93051. View